Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
The approval applies to those between 12 and 17 years old who have any of the six genotypes of the virus.
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
The two-drug regimen can cure the virus in as little as eight weeks.
AbbVie’s ’3D’ regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV
Sovaldi (sofosbuvir) and ribavirin cured between 84 percent and 91 percent of people coinfected with HIV and genotypes 1 through 4 of hep C.
Victrelis (boceprevir), Merck’s hepatitis C virus (HCV) protease inhibitor, should not be combined with the following Norvir (ritonavir)...
Important preliminary recommendations involving the use of hepatitis C protease inhibitors among people living with HIV are provided by U.S. D...
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted p...
The odds of curing hep C are now better than ever.
Vertex Pharmaceuticals? hepatitis C virus (HCV) protease inhibitor telaprevir interacts to varying degrees with commonly used HIV antiretrovir...
The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.